Skip to content

Welcome to Discover Pharma! Today is : October 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

FDA

  • Advanced Therapies,Clinical & Regulatory,Genomics and sequencing,Pharmaceuticals and therapeutics,Research & Development

    Atsena receives EMA orphan designation for two inherited retinal disease gene therapies

    Atsena Therapeutics has received EMA orphan designation for two gene [...]

    July 24, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Medicus receives FDA feedback and IRB approval for Teverelix Phase 2 urinary retention trial

    Medicus Pharma has received positive feedback from FDA and central [...]

    July 20, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China

    Adneuris Therapeutics has granted Zhejiang Conba Pharmaceutical exclusive rights to [...]

    July 15, 2026
  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development

    Revita maintains GLP-1 weight loss one year after treatment discontinuation in REMAIN-1 trial

    Fractyl Health has reported positive one-year data from the midpoint [...]

    July 16, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA grants Fast Track status to SOTIO’s colorectal cancer ADC ahead of Phase 1/2 trial

    The US FDA has granted Fast Track Designation to SOTIO [...]

    July 14, 2026
  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Therapeutic Areas

    Theranica expands Nerivio migraine device coverage to more than half of insured Americans

    Theranica’s Nerivio wearable migraine therapy is now covered by health [...]

    July 13, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics

    Fonseca Biosciences launches XTORO after FDA clears US commercial manufacturing

    Fonseca Biosciences has launched XTORO (finafloxacin otic suspension) 0.3% in [...]

    July 9, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    FORE Biotherapeutics completes enrolment in registrational plixorafenib brain tumour study

    FORE Biotherapeutics has completed target enrolment in the primary central [...]

    July 8, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Compass reports second positive Phase 3 trial of psilocybin therapy for treatment-resistant depression

    Compass Pathways has reported positive six-month results from its second [...]

    July 8, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Healome raises £2M to advance eye-drop technology for ocular surface diseases

    Healome Therapeutics has raised £2 million in seed funding to [...]

    July 8, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • ViiV’s Cabenuva achieves superior viral suppression in CROWN Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Shift Bioscience publishes AI virtual cell framework for target discovery
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top